DOCSLIB.ORG

Immunological Challenges Associated with Artificial Skin Grafts: Available Solutions and Stem Cells in Future Design of Synthetic Skin Saurabh Dixit1,2†, Dieudonné R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunological Challenges Associated with Artificial Skin Grafts: Available Solutions and Stem Cells in Future Design of Synthetic Skin Saurabh Dixit1,2†, Dieudonné R Dixit et al. Journal of Biological Engineering (2017) 11:49 DOI 10.1186/s13036-017-0089-9 REVIEW Open Access Immunological challenges associated with artificial skin grafts: available solutions and stem cells in future design of synthetic skin Saurabh Dixit1,2†, Dieudonné R. Baganizi1†, Rajnish Sahu1†, Ejowke Dosunmu1, Atul Chaudhari1, Komal Vig1, Shreekumar R. Pillai1, Shree R. Singh1 and Vida A. Dennis1* Abstract The repair or replacement of damaged skins is still an important, challenging public health problem. Immune acceptance and long-term survival of skin grafts represent the major problem to overcome in grafting given that in most situations autografts cannot be used. The emergence of artificial skin substitutes provides alternative treatment with the capacity to reduce the dependency on the increasing demand of cadaver skin grafts. Over the years, considerable research efforts have focused on strategies for skin repair or permanent skin graft transplantations. Available skin substitutes include pre- or post-transplantation treatments of donor cells, stem cell-based therapies, and skin equivalents composed of bio-engineered acellular or cellular skin substitutes. However, skin substitutes are still prone to immunological rejection, and as such, there is currently no skin substitute available to overcome this phenomenon. This review focuses on the mechanisms of skin rejection and tolerance induction and outlines in detail current available strategies and alternatives that may allow achieving full-thickness skin replacement and repair. Keywords: Skin allograft, Immune rejection, Biomaterial, Scaffolds, Stem cells, Skin tissue engineering, Skin substitutes Background severe skin injuries to protect the exposed layers of skin The skin, a subcomponent of the integumentary system, and allow the damaged portion to reform. Transplanting is a substantial fast-growing organ comprised of the epi- autologous skin grafts [4, 5] is the therapeutic approach dermis, dermis and hypodermis layers, which in adults of choice that successively reform the skin, but extensive weighs about 7–8 pounds, covering 21–22 square feet of injuries and chronic skin wounds could result in an in- surface area (2-m square). The skin is a protective bar- sufficient number of autografts, especially in severe burn rier for toxins, micro-organisms, radiation, and mechan- cases [6] and skin morbidities [7, 8]. When required, in ical impacts along with regulating several physiological such cases, either allogeneic or xenogeneic, skin grafts functions including temperature control, preventing de- are used for transplantation. Despite allogeneic trans- hydration and providing sensory detection and immune plantations becoming more tolerant with immunosup- surveillance [1, 2]. Human skin frequently is damaged/ pressive treatment, there are still some issues with early injured resulting in the loss of its integrity and physio- rejection. Skin allograft rejection is the recipient’s im- logical balance, which may result in significant disability mune response following the recognition of alloantigens and infections. The skin’s natural restorative capacity leading to the cellular destruction. Allogeneic or xeno- usually is sufficient to repair and heal itself when dam- geneic skin grafts may be employed but their short-term aged/injured [3]. However, skin grafts are required for graft survival time limits their clinical use [9]. Skin allo- grafts transplantation is employed for severe clinical cases to protect the damaged skin areas, but considering * Correspondence: [email protected] † the conundrum of the rejection mechanism, the recipi- Equal contributors 1Center for Nanobiotechnology Research and Department of Biological ent may require additional transplantation from a differ- Sciences, Alabama State University, 1627 Harris Way, Montgomery, AL 36104, ent donor [10]. Alternative strategies are now being USA developed to overcome skin allograft rejections and Full list of author information is available at the end of the article © The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Dixit et al. Journal of Biological Engineering (2017) 11:49 Page 2 of 23 allowing adequate skin repair [11, 12]. Novel treatment this functionality with adoptive transfer of normal T cells approaches include the use of stem cell-based therapies, initiates rejection of the skin graft [25, 26]. Therefore, a specific immunosuppressive therapies targeting T cells hurdle in allogeneic skin grafting is the triggering of or donor immune cells and skin tissue engineering. Sev- CD4+ and CD8+ T cells immune responses, sometimes eral tissue-engineered skin substitutes are commercially involving both for first set rejection, although second set available and used in clinical settings with negligible risk rejection could be facilitated by antibodies [26]. of immunogenic responses such as the Integra dermal The mechanism of skin graft rejection (Fig. 1) starts regeneration template [13]. Available engineered skin with responses from dendritic cells (DCs), macrophages, substitutes are composed of either a cellular or acellular polymorphonuclear cells, angiogenic mediators, and cy- component and a biological (autologous, allogeneic, and tokines to promote rejection [22, 23], followed subse- xenogeneic) or synthetic (polymer) scaffold [14]. quently by the activation of T cells (CD4+ and CD8+). However, available skin alternatives engineered to Further, accumulation of inflammatory cytokines and ef- mimic natural skin still do not provide a permanent so- fector T cells permeate the skin graft to commence re- lution [5, 14, 15]. This review gives an insight into jection [22, 26, 27]. The event/stimulus that triggers skin different approaches and innovative advances to allow graft rejection arises from a mismatch in donor MHC overcoming skin allografts rejection. and recipient T cells receptors (TCRs) [28]. Even though matching the MHC type is critical in avoiding skin grafts Immunological rejection rejection, a single genetic difference at the loci of MHC Mechanisms of skin graft rejection molecules can still commence the rejection process by Allografts have been used for many years in transplant- stimulating alloreactive T cells [10]. Additionally, even if ation; however, donor tissue availability remains a critical the rejection rate is not very high in genetically related issue. Cadaver tissues, especially organs, are in high de- donor and recipient [29], it can be controlled by im- mand and harvesting of skin has to be completed rapidly munosuppressive drugs. The only scenario where allo- [16] post-death and preserved [17]. Critical issues associ- graft transplantation without immunosuppressive drugs ated with allografts are availability and rejection. is successful when the donor and recipient are identical Laboratory-grown artificial tissues are now in develop- twins, with true human leukocyte antigen (HLA) match ment to help overcome the immunological rejection is- [30], which shows the immunological importance of sues [18, 19]. Over the years, synthetic skins comprised MHC molecules in rejection of transplants. Thus match- mostly of human cell lines with biodegradable materials ing the HLA types [31] between non-identical twins have been used for transplantation onto burned and wounded skin patients [20, 21]. Even though the artifi- cial skin products are in development and available com- mercially, they are still prone to rejections [7]. Skin autografts transplantation is a well-known med- ical procedure. Grafting between genetically identical in- dividuals (syngeneic graft) can be successful without a prolonged immunosuppressive treatment. Even though immunosuppressive treatments for organ transplantation are effective in preventing early rejection, skin tissues whether from both donor or engineered are continu- ously failing [22]. Skin graft successfully placed at the donor site but rejected within 1–2 weeks is consistent and is termed first set rejection. The second set of rejec- tion is even faster if grafted from the same donor. Graft rejection is an intricate mechanism, which involves an array of processes and ultimately potent inflammatory responses initiated by innate immune responses and de- struction of the donor tissue [23]. The rate of rejection ’ of donor tissue at the recipient s graft site is dependent Fig. 1 Allorecognition pathways: Direct pathway is the process on the graft volume and antigens incompatibilities be- whereby the donor’s MHC molecules on APCs is recognized by the tween both. The role of T lymphocytes in graft rejection TCRs of recipient’s T cells. Indirect pathway recognizes the processed is vital as evidenced from studies in nude mice, which peptide presented by recipient’s MHC on APCs. Semi-direct pathway is ’ do not reject allogeneic skin grafts because they lack where T cell activation occurs by transfer of the donorsMHContothe recipient’sAPCs CD4+ and CD8+ functionality [24]; however restoring Dixit et al. Journal
Load more

Recommended publications
  • Transplantation and Hepatic Pathology University of Pittsburgh Medical Center November, 2007
    Resident Handbook Division of Transplantation and Hepatic Pathology University of Pittsburgh Medical Center November, 2007 For private use of residents only- not for public distribution Table of Contents Anatomic Transplantation Pathology Rotation Clinical Responsibilities of the Division ........................................................3 Categorizations of Specimens and Structure of Signout.................................3 Resident Responsibilities................................................................................4 Learning Resources.........................................................................................4 Transplantation Pathology on the World-Wide Web......................................4 Weekly Schedule ............................................................................................6 Staff Locations and Telephone Numbers........................................................7 Background Articles Landmarks in Transplantation ........................................................................8 Trends in Organ Donation and Transplantation US 1996-2005.....................18 Perspectives in Organ Preservation………....................................................26 Transplant Tolerance- Editorial……………………………………….…….36 Kidney Grading Systems Banff 2005 Update……………………….....................................................42 Banff 97 Components (I t v g etc.) ................................................................44 Readings Banff 05 Meeting Report………………………………………...................47
    [Show full text]
  • Msc Payment Schedule Index
    MSC PAYMENT SCHEDULE INDEX SECTIONS (To go directly to the an applicable section of the Payment Schedule, click on the Section heading listed below) GENERAL PREAMBLE TO THE PAYMENT SCHEDULE .................................. 1 2. OUT-OF-OFFICE HOURS PREMIUMS ............................................................... 2 3. GENERAL SERVICES ......................................................................................... 3 4. DIAGNOSTIC AND SELECTED THERAPEUTIC PROCEDURES ...................... 4 5. CRITICAL CARE .................................................................................................. 5 6. EMERGENCY MEDICINE .................................................................................... 6 7. GENERAL PRACTICE ......................................................................................... 7 8. ANESTHESIA ...................................................................................................... 8 9. DERMATOLOGY ................................................................................................. 9 10. OPHTHALMOLOGY .......................................................................................... 10 11. OTOLARYNGOLOGY ........................................................................................ 11 12. GENERAL INTERNAL MEDICINE .................................................................... 12 13. CARDIOLOGY ................................................................................................... 13 14. CLINICAL IMMUNOLOGY AND ALLERGY
    [Show full text]
  • Ultra Pure Collagen Regenerative Medicine
    ENG Ultra pure collagen Regenerative medicine Because we are committed to limiting uncertainty, Specifications Integra continues to develop new products in regenerative technology. • An established product line with proven results. • Outstanding safety profile. • Integra LifeSciences has leveraged over 30 years of science and innovation in the development of • Implanted in over 900 000 patients. collagen technology. • Integra LifeSciences’ extensive collagen purification process, advanced bio-engineering proficiency, and manufacturing experience add value to our products designed for protection, regeneration and repair of human tissue in various clinical applications. • Ultra Pure Collagen™ is the base material of implants used successfully in over 10 million procedures worldwide. • Ultra Pure Collagen™ has been used in general surgery, burn surgery, neurosurgery, plastic and reconstructive surgery, peripheral nerve/tendon surgery & orthopedic surgery. Products for sale in Europe, Middle-East and Africa only Ultra pure collagen Regenerative medicine How was Integra LifeSciences’ Collagen Matrix Created? For over thirty years, Integra LifeSciences has been a leader in developing and manufacturing high quality collagen implants. In the early 1970’s, John F. Burke, MD, chief of Trauma Services at Massachusetts General Hospital and Shriners Burns Institute, identified the need to improve skin restoration of severely burned patients. While patient related donor skin was an option, immunorejection was a critical issue. Dr. Burke theorized that an artificial means to cover the skin might offer positive results without the potential for donor skin rejection. Dr. Burke collaborated with Dr. Ioannas Yannas, a professor What Makes Integra LifeSciences’ Collagen at MIT with a specialization in material sciences and Unique? physical chemistry, to develop a biocompatible product to improve wound healing.
    [Show full text]
  • Skin Grafts in Cutaneous Oncology* Enxertia De Pele Em Oncologia
    RevABDV81N5.qxd 07.11.06 17:07 Page 465 465 Artigo de Revisão Enxertia de pele em oncologia cutânea* Skin grafts in cutaneous oncology* José Anselmo Lofêgo Filho1 Paula Dadalti2 Diogo Cotrim de Souza3 Paulo Roberto Cotrim de Souza4 Marcos Aurélio Leiros da Silva5 Cristina Maeda Takiya6 Resumo: Em oncologia cutânea depara-se freqüentemente com situações em que a confec- ção de um enxerto é uma boa alternativa para o fechamento do defeito cirúrgico. Conhecer aspectos referentes à integração e contração dos enxertos é fundamental para que os cirur- giões dermatológicos procedam de maneira a não contrariar princípios básicos do trans- plante de pele. Os autores fazem uma revisão da classificação e fisiologia dos enxertos de pele, acrescendo considerações cirúrgicas determinantes para o sucesso do procedimento. Palavras-chave: Neoplasias cutâneas; Transplante de pele; Transplante homólogo Abstract: In cutaneous oncology, there are many situations in which skin grafts could be a good alternative for closing surgical defect. Dermatological surgeons should have enough knowledge about graft integration and contraction in order to not contradict the basic prin- ciples of skin transplantation. The authors review skin graft classification and physiology and make some surgical considerations on successful procedures. Keywords: Skin neoplasms; Skin transplantation; Transplantation, homologous INTRODUÇÃO Enxerto é parte de um tecido vivo transplanta- tológica. São simples quando apresentam um único do de um lugar para outro no mesmo organismo ou tipo de tecido e compostos quando constituídos de em organismos distintos.1 Contudo, a utilização da dois ou mais tipos de tecidos. Em oncologia cutânea, terminologia enxerto para designar uma modalidade um enxerto composto é usado quando o defeito cirúrgica, apesar de errônea, tornou-se coloquial.
    [Show full text]
  • AMRITA HOSPITALS AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR)
    AMRITA HOSPITALS HOSPITALS AMRITA AMRITA AMRITA HOSPITALS HOSPITALS Kochi * Faridabad (Delhi NCR) Kochi * Faridabad (Delhi NCR) A Comprehensive A Comprehensive Overview Overview A Comprehensive Overview AMRITA INSTITUTE OF MEDICAL SCIENCES AIMS Ponekkara P.O. Kochi, Kerala, India 682 041 Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org Copyright@2018 AMRITA HOSPITALS Kochi * Faridabad (Delhi-NCR) A COMPREHENSIVE OVERVIEW A Comprehensive Overview Copyright © 2018 by Amrita Institute of Medical Sciences All rights reserved. No portion of this book, except for brief review, may be reproduced, stored in a retrieval system, or transmitted in any form or by any means —electronic, mechanical, photocopying, recording, or otherwise without permission of the publisher. Published by: Amrita Vishwa Vidyapeetham Amrita Institute of Medical Sciences AIMS Ponekkara P.O. Kochi, Kerala 682041 India Phone: (91) 484-2801234 Fax: (91) 484-2802020 email: [email protected] website: www.amritahospitals.org June 2018 2018 ISBN 1-879410-38-9 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA AMRITA HOSPITALS KOCHI * FARIDABAD (DELHI-NCR) A COMPREHENSIVE OVERVIEW 2018 Amrita Institute of Medical Sciences and Research Center Kochi, Kerala INDIA CONTENTS Mission Statement ......................................... 04 Message From The Director ......................... 05 Our Founder and Inspiration Sri Mata Amritanandamayi Devi .................. 06 Awards and Accreditations .........................
    [Show full text]
  • Hesitant Steps from the Artificial Skin to Organ Regeneration
    Hesitant steps from the artificial skin to organ regeneration The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Yannas, Ioannis V. “Hesitant Steps from the Artificial Skin to Organ Regeneration.” Regenerative Biomaterials (June 26, 2018). As Published http://dx.doi.org/10.1093/RB/RBY012 Publisher Oxford University Press (OUP) Version Final published version Citable link http://hdl.handle.net/1721.1/120040 Terms of Use Creative Commons Attribution 4.0 International license Detailed Terms https://creativecommons.org/licenses/by/4.0/ Regenerative Biomaterials, 2018, 189–195 doi: 10.1093/rb/rby012 Advance Access Publication Date: 26 June 2018 Review Hesitant steps from the artificial skin to organ regeneration Ioannis V. Yannas* Downloaded from https://academic.oup.com/rb/article-abstract/5/4/189/5045640 by MIT Libraries user on 14 January 2019 Department of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA *Correspondence address. Department of Mechanical Engineering, Massachusetts Institute of Technology, Room 3-332, 77 Mass. Ave., Cambridge, MA 02139-4307, USA. E-mail: [email protected] Received 7 May 2018; accepted on 10 May 2018 Abstract This is a historical account of the steps, both serendipitous and rational, that led my group of stu- dents and colleagues at MIT and Harvard Medical School to discover induced organ regeneration. Our research led to methods for growing back in adult mammals three heavily injured organs, skin, peripheral nerves and the conjunctiva. We conclude that regeneration in adults is induced by a modification of normal wound healing.
    [Show full text]
  • Clinical Considerations in Facial Transplantation
    CLINICAL CONSIDERATIONS IN FACIAL TRANSPLANTATION by Anthony Renshaw A thesis submitted in fulfilment of the requirements of University College London for the degree of Doctor of Medicine January 2011 Department of Plastic and Reconstructive Surgery, Academic Division of Surgical & Interventional Sciences, University College London 1 Declaration I, Anthony Renshaw, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis The copyright of this thesis rests with the author and no quotation from it or information derived from it may be published without the prior written consent of the author. …………………………………………………………. 2 Abstract Facial transplantation has emerged as the next step on the reconstructive ladder for severe facial disfigurement. Clinical issues surrounding facial tissue donation are examined, comprising pre-transplant facial vessel delineation; pre-operative aesthetic matching; and attitudes towards donation. An anatomical study of 200 consecutive facial and transverse facial vessels was performed using colour Doppler ultrasound. Facial vessels were measured at three landmarks and their branching pattern documented. The facial artery main branch was detected at the lower mandibular border in 99.5% of cases, the accompanying facial vein in 97.5%. The transverse facial artery was present in 75.5% of cases, the vein found in 58%. When the facial artery was undetectable, there was transverse facial artery dominance. When the facial vein was absent it was replaced with a transverse facial vein. This provides valuable pre-operative information regarding vessel status. A quantitative eleven- point skin tonal matching scheme is described using digital analysis of facial imagery.
    [Show full text]
  • 78581/2020/Estt-Ne Hr
    105 78581/2020/ESTT-NE_HR 1| T a r i f f - AIMS 106 78581/2020/ESTT-NE_HR INDEX 1. General Information ( Section A) 3 i. Out Patient Department ii. Ambulance Charges 2. General Information ( Section B) 5 i. Bed charges ii. In patient Consultation fees iii. Billing Of Surgery Anesthesia and OT Charges iv. Billing Of Surgery /Procedure/ others 3. LAB 9 4. Outsouce Lab 16 5. Blood Bank 64 6. Imaging & Radiodiagnosis 65 7. Non – Invasive Lab 80 8. Anesthesia 82 9. Cardiology and Cardiac Surgery 84 10. Critical Care Services 89 11. Baby Care 91 12. Common Procedure 94 13 Dental 94 14 Dermatology 101 15 E N T 105 16 Gastroenterology 110 17 Maxillo Facial Surgery 113 18 Nephrology 116 19 Neuro Diagnostic Lab 118 20 Oncology 112 21 Ophthalmology 136 22 Orthopedies 142 23 OBS & Gynaecology 149 24 Physiotherapy 154 25 Respiratory Medicine 156 26 Surgery & Major Procedures i. General Surgery 158 ii. Pediatric Surgery 165 iii. PlasticSurgery 170 iv. Neuro Surgery 182 27 Urology 185 28 Interventional Radiology 192 29 Interventional Pain Management 194 30 Paediatric Cardiac Surgery 197 31 Bed Side Service Charges200 2| T a r i f f - AIMS 107 78581/2020/ESTT-NE_HRSection – A GENERAL INFORMATION OUT PATIENT DEPARTMENT OPD Consultations: Superspeciality OPD Consultation * Rs. 700 Specialty OPD Consultation** Rs. 400 to 800 Note: OPD Timing Monday- Saturday ( 8:00AM – 7:00PM) *Super specialty Departments – Cardiac Surgery, Cardiology, Neurology, Neurosurgery, Oncology, Respiratory Medicine, Urology, Plastic Surgery, Gastroenterology, Endocrinology, Paediatric
    [Show full text]
  • Skin Resurfacing for the Burned Patient
    00. ם NEW DIRECTIONS IN PLASTIC SURGERY, PART II 0094–1298/02 $15.00 SKIN RESURFACING FOR THE BURNED PATIENT Ryan A. Stanton, MD, and David A. Billmire, MD The ultimate goal and eventual reward in factory quality of life and adapt a functional treating severely burned patients is the estab- postburn lifestyle. A rough indicator of indi- lishment of a protective barrier from the out- vidual psychologic rehabilitation is reflected side world. Skin resurfacing for the burned by employment status. Patients who return to patient has made large strides since the mid- work after burn injury have less behavioral twentieth century. Improvements in resuscita- avoidance, higher self esteem, and greater at- tion, management of inhalation injuries, and tention to goals. It has been shown that the other advances in critical care are responsible most significant predictors of return to work for survival rates in burned patients nearly are involvement of the hand, grafting, size of doubling since the 1950s, increasing by al- burn, and age. Patients younger than 45 have most 1% each year.49, 57 Several factors have a higher return to work rate.74 The care of a contributed extensively to the evolution of severely burned patient requires the infra- clinical burn care, including a better under- structure of a dedicated burn center with in- standing of the critical need for adequate terdisciplinary involvement of nursing, coun- fluid resuscitation immediately postburn, seling, group therapy, and occupational and prophylaxis against wound sepsis and its physical therapy. Interventions designed to complications, the importance of adequate aid adjustment, work hardening, and other nutritional support, burn pathophysiology rehabilitative services and marital and family and its inflammatory mediators, management therapy are also important.
    [Show full text]
  • Skin Grafting in the Dog Elroy C
    Volume 19 | Issue 3 Article 1 1957 Skin Grafting in the Dog Elroy C. Jensen Iowa State College Follow this and additional works at: https://lib.dr.iastate.edu/iowastate_veterinarian Part of the Small or Companion Animal Medicine Commons, and the Veterinary Anatomy Commons Recommended Citation Jensen, Elroy C. (1957) "Skin Grafting in the Dog," Iowa State University Veterinarian: Vol. 19 : Iss. 3 , Article 1. Available at: https://lib.dr.iastate.edu/iowastate_veterinarian/vol19/iss3/1 This Article is brought to you for free and open access by the Journals at Iowa State University Digital Repository. It has been accepted for inclusion in Iowa State University Veterinarian by an authorized editor of Iowa State University Digital Repository. For more information, please contact [email protected]. SKIN GRAFTING In The Dog Elroy C. J,ensen, D.V.M. THERE are several histological factors the arm instead of from the forehead. which have made skin grafting pos­ This technique is now known as the Ital­ sible in man and animals. First, the com­ ian method of rhinoplasty. Free skin parative ease which epithelium can regen­ grafting started early in the 19th century erate is a factor. This new growth of tis­ by two charlatans which is related by sue occurs either from the periphery of a Baroni, the physi'Ologist, "A woman wound or it may result from proliferation named Gamba Curat, in order to show of the external root sheath of the hair the efficiency of an ointment she was sel­ follicles providing the dermis has not been ling, cut a piece of skin from her thigh completely destroyed.
    [Show full text]
  • Role of Ia-Like Products of the Main Histocompatibility Complex in Conditioning Skin Allograft Survival in Man
    Role of Ia-Like Products of the Main Histocompatibility Complex in Conditioning Skin Allograft Survival in Man J. Dausset, … , T. Meo, F. T. Rapaport J Clin Invest. 1979;63(5):893-901. https://doi.org/10.1172/JCI109389. Research Article This report correlates the survival time of 93 intrafamilial skin allografts performed under conditions of main histocompatibility complex (HLA) haploidentity with donor-recipient compatibility for products of the HLA-A, -B, -C, and - DR, as well as C3 proactivator, Glyoxalase I, and P loci located on the human 6th chromosome. Incompatibilities for HLA- A and -B (and to a lesser extent for HLA-C) and(or) for HLA-DR products exerted a strong influence upon the fate of skin allografts. When HLA-A and -B were considered alone, the most compatible group of grafts had a mean survival time of 15.8 d, as compared with 11.3 d for the most incompatible transplants. HLA-DR compatibility alone was associated with a mean survival time of 15.3 d, whereas HLA-DR-incompatible grafts had a mean survival time of 11.5 d. Incompatibilities for C3 proactivator, Glyoxalase I, and P did not have a significant effect upon graft survival. There was no evidence of an association between donor-recipient incompatibility at HLA-A, -B, or -C or at HLA-DR; such incompatibilities occurred independently of each other, in spite of the state of linkage disequilibrium known to exist between HLA-B and -DR. Incompatibilities for HLA-A, -B, and for HLA-DR exerted a potent additive effect upon graft survival.
    [Show full text]
  • Historic Landmarks in Clinical Transplantation: Conclusions from the Consensus Conference at the University of California, Los Angeles
    World J. Surg.24, 834-843, 2000 DOl: 10.1007/5002680010134 WORLD Journal of SURGERY © .lOOO by rhe Societe Internationale J(" Ch!wrgie Historic Landmarks in Clinical Transplantation: Conclusions from the Consensus Conference at the University of California, Los Angeles Carl G. Groth, M.D., Ph.D.,l Leslie B. Brent, B.Sc., Ph.D} Roy Y. Caine, M.D} Jean B. Dausset, M.D., Ph.D.,4 Robert A. Good, M.D., Ph.D.,s Joseph E. Murray, M.D.,6 Norman E. Shumway, M.D., Ph.D} Robert S. Schwartz, M.D} Thomas E. Starzl, M.D., Ph.D} Paul I. Terasaki, Ph.D.,l° E. Donnall Thomas, M.D}l Jon J. van Rood, M.D., Ph.DY 1Department of Transplantation Surgery, Karolinska Institute, Huddinge Hospital, SE-141 86 Huddinge, Sweden 230 Hugo Road, Tufnell Park, London N19 5EU, UK 'Department of Surgery, University of Cambridge, Douglas House Annexe, 18 Trumpington Road, Cambridge CB2 ZAH, UK "Foundation Jean Dausset-C.E.P.H., 27 rue Juliette Dodu, 75010 Paris Cedex, France 5Department of Pediatrics, Division of Allergy and Immunology, All Children's Hospital, 801 Sixth Street South, SI. Petersburg, Florida 33701, USA "Department of Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA 'Department of Cardiothoracic Surgery, Falk Cardiovascular Research Center, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305-5247, USA 'The New England Journal of Medicine, 10 Shattuck Street, Boston, Massachusetts 02115-6094, USA 9Department of Surgery, University of Pittsburgh, School of Medicine, Thomas E. Starzl Transplantation Institute, 3601 Fifth Avenue, Pittsburgh, Pennsylvania 15213, USA 1012835 Parkyns Street, Los Angeles, California 90049, USA lIDepartment of Medicine, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, PO Box 19024, Seattle, Washington 98109-1024, USA 12Department of Immunohematology and Blood Bank, University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands Abstract.
    [Show full text]